





PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number 10/761,717

Filing Date January 20, 2004

First Named Inventor Yukun SUN

Art Unit unknown

Examiner Name unknown

Attorney Docket Number 291-0002US

Sheet

2

of

2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SL		HUI, H, Glucagon-Like Peptide 1 Induces Differentiation of Islet Duodenal Homeobox-1- Positive Pancreatic Ductal Cells Into Insulin-Secreting Cells, Diabetes, April 2001, pp. 785-796, Vol. 50.	
SL		NIELSEN, J, Regulation of B-Cell Mass by Hormones and Growth Factors, Diabetes, February 2001, pp. 825-829, Vol. 50. Supplement 1.	
SL		RACHMAN, J., Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7-36) Amide in Patients with NIDDM, Diabetes, November 1996, pp. 1524-1530, Vol. 45.	
SL		TOURREL, C., Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the B-Cell Mass During the Prediabetic Period With Glucagon-Like Peptide-1 or Exendin-4, Diabetes, May 2002, pp. 1443-1452, Vol. 51.	

Examiner  
Signature

07/10/2006

Date  
Considered

07/10/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.